March 2026 • PharmaTimes Magazine • 4-5

Contents

Features

NHS after the next election – futures pharma should be planning for

Withdrawal of USAID is fanning winds of entrepreneurial change

Intriguing notes from the frontline of the ‘Age of the Oocyte’

GLP-1s are reshaping the UK and pharma must prepare for next chapter

The next phase of agentic AI – autonomy with accountability

Analysis

Preventative revolution – redefining the role of GLP-1s in healthcare

GLP-1 boom is exposing limitations of pharma supply chains

The 15 most kick-ass pharma products of the past 15 years

MASLD isn’t silent. It’s definitely speaking loud and clear

Radiotherapy’s capacity is holding cancer treatment back

SmartPeople

18.
Leading by example
A journey from community pharmacy to medical leadership

24.
Talking the talk
It’s the start of a beautiful friendship, as Jess takes to the page

36.
Very moving indeed
The pharma folk tasked with remembering new colleagues' names